Capping cancer drug margins is only step one — patients must feel the savings, says former NHA CEO
The National Pharmaceutical Pricing Authority's (NPPA) decision to cap trade margins on 137 anti-cancer medicines is an important step towards reducing the financial burden of cancer treatment, but its success will depend on whether the savings actually reach patients, healthcare policy expert Indu Bhushan has said.
Dr. Bhushan, former chief executive officer of the National Health Authority, made the observation in an exclusive interview with The Hindu. The revised prices are scheduled to take effect from November 9.
The NPPA's order works by limiting the margin that can be charged at each stage of the supply chain — from manufacturer to distributor to retailer — rather than fixing a single retail price. Trade margin rationalisation is one of several tools available to regulators and has been used in the past for select medicines and medical devices. Its central promise is that a ceiling on the mark-up collected along the way should bring down what a patient finally pays at the pharmacy counter.
Dr. Bhushan said the intervention could substantially reduce costs for patients who require prolonged treatment. Cancer care frequently involves extended courses of therapy, repeat cycles and combinations of drugs, and the cumulative expense can be considerable for households paying out of pocket.
His more cautious point was about delivery. A price notification on paper does not by itself guarantee relief, and the measure's real test will be whether the difference is visible to patients. "Financial protection for patients cannot be achieved through a single intervention," he said, indicating that price regulation must work alongside other elements of the health system if households are to be shielded from catastrophic costs.
The remark reflects a long-standing concern in health policy: that multiple steps sit between a regulatory order and a patient's bill, and that each of them can absorb part of an intended benefit. For that reason, attention will now turn to implementation — how NPPA monitors compliance across manufacturers and the distribution chain, and whether hospitals and pharmacies pass on the revised prices.
It is also not yet clear how large the reduction will be for individual medicines, since the impact of a margin cap varies with the existing pricing structure of each product. The picture will become clearer once the revised prices come into force and are compared with what patients were being charged earlier.
Cancer treatment is among the most expensive categories of healthcare, and the cost of medicines forms a significant share of the total. For families without adequate insurance cover, a diagnosis can quickly translate into debt or the abandonment of treatment. Expensive medicines have therefore been a recurring focus of price regulators.
Public health researchers generally describe such measures as necessary but partial. Lower drug prices help, but financial protection also depends on the breadth of insurance coverage, the availability of generic alternatives, the pricing of diagnostics and hospital care, and the ability of patients to access treatment close to home.
For now, the NPPA's decision gives patients and their families a reason to watch the November 9 rollout closely. The measure's value will be judged not by the order itself, but by what it changes at the counter where medicines are bought.
